DEPARTMENT OF PATHOLOGY

Thomas A. Lane, M.D.

Thomas Lane, MD

  • Professor
  • Director of Transfusion Medicine and Cellular Therapy
  • B.S. - College of William and Mary, 1965
  • M.D. - Jefferson Medical College, 1969
  • Board Certifications: Internal Medicine, Hematology, Blood Banking
  • Clinical Speciality: Transfusion Medicine, Cell Therapy, Hematology

Research Interests

  1. The mobilization of hematopoietic stem cells and progenitor cells into the peripheral blood through the use of cytokines. The long term goal of these studies is to establish improved methods of harvesting stem cells for allogeneic marrow transplantation and gene therapy.
  2. Cell Therapy and Hematopoietic Stem Cell Processing.
  3. Adoptive immunotherapy for acute myelogenous leukemia.

Dr. Lane's lab and research activities center around the technology of providing hematopoietic grafts for bone marrow transplant candidates. He works in the field of hematopoietic stem cell mobilization and processing to support marrow transplantation and collaborates with investigators in the marrow transplant program toward development of cell therapies. We have recently entered into a collaborative effort with investigators at UC Irvine and Burnham Inst., in a research project funded by the NIH (S. Cramer, PI at UCI) toward the development of a Phase I clinical trial of autologous marrow stromal cells (MSC) in patients with ischemic stroke.

Representative Publications

  1. Lane TA, Ho AD, Bashey A, Peterson S, Young D, and Law P. Mobilization of Blood-Derived Stem and Progenitor Cells In Normal Subjects By Granulocyte-Macrophate and Granulocyte-Colony Stimulating Factor. Transfusion, 1999; 39:39-47.
  2. Lane, TA, Bashey A, Carrier E, Holman P, Castro J, Mullen M, Ward D, Ada O, Ball E Improving the efficiency of peripheral blood progenitor cell collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy 2004;6(4):318-327.
  3. Lane, TA. Umbilical cord blood grafts for hematopoietic transplantation in adults: a cup half empty or half full? Transfusion. 2005 Jun;45(6):1027-34.
  4. Zhong RK., Loken M.R., Lane T.A., Ball E.D. CTLA-4 blockade by a human monoclonal antibody enhances the capacity of AML-derived dendritic cells to induce T cell responses against AML cells in an autologous culture system. Cytotherapy, 2006;8(1):3-12.
  5. Lane TA, Mackintosh E, Garls D, and Cramer S. Marrow Stromal Cell (MSC) Growth from long term Cryopreserved Bone Marrow. Blood. 2006;108(11, pt 2):398b (Abstract).
  6. Click here to search for Dr. Lane's publications

Biography

Dr. Lane is a graduate of the College of William and Mary, Williamsburg, Virginia, where he obtained his bachelor of science degree in Chemistry before graduating in 1969 with his M.D. degree from Jefferson Medical College, Philadelphia. He was a resident in Medicine at Mary Hitchcock Memorial Hospital in Hanover, New Hampshire and in Hematology at Thomas Jefferson University hospital from 1970-1975 (split by 2 years of service in the Armed Forces). His training in Transfusion Medicine took place at the New York Blood Center from 1975-1976. Dr. Lane came to UCSD in 1976 as Assistant Professor of Pathology in Residence. He became Professor of Pathology in 1990. From 1976 through 1990 he served as Director of the Blood Bank at the Veterans Administration Medical Center and since 1990 has been the Medical Director of the Transfusion Service at UCSD Medical Center, which is accredited by AABB, CAP and registered with FDA.

Dr. Lane continues to serve as Medical Director of two busy services, the UCSD-MC, Hillcrest Transfusion Service and the UCSD-MC Stem Cell Processing Laboratory (SCPL), where he also serves as Laboratory Director. The UCSD SCPL is a component of the Department of Medicine, Division of Blood and Marrow Transplant and its primary mission is to support the cell therapy requirements of that program. The UCSD Stem Cell Processing Laboratory is accredited by the AABB and Foundation for Accreditation of Cell Therapy (FACT) and is FDA-registered for Cellular Therapy. The SCPL supports a wide variety of clinical trials in marrow transplant and was recently selected to serve as the cell therapy laboratory to support a novel clinical trial of autologous marrow stromal cells in patients with ischemic stroke.

Click here to contact me

Page 'Breadcrumb' Navigation:

External Resources: